The FDA has approved drotrecogin alfa (activated) (Xigris, Eli Lilly, Indianapolis), a recombinant form of human activated protein C, for the reduction of mortality in adults with severe sepsis (associated with acute organ dysfunction).
The effectiveness of the drug was shown in a multicenter, randomized, double-blind, placebo-controlled trial of 1690 adult patients with severe sepsis. Entry criteria included a systemic inflammatory response presumed due to infection and at least one of the following: cardiovascular, respiratory, or renal dysfunction; thrombocytopenia; or metabolic acidosis.
Schwetz BA. Drug for Severe Adult Sepsis. JAMA. 2002;287(1):33. doi:10.1001/jama.287.1.33
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: